Conexeu Sciences Inc. saw its stock respond positively after management disclosed forward movement on manufacturing work for its lead wound care device candidate, CXU. The company reported a 6.3% rise in its shares on Monday following the update.
Manufacturing and scale-up activity
Conexeu said it has transferred its standardized formulation methods to a contract development and manufacturing organization (CDMO) and is progressing manufacturing scale-up efforts intended to support production of CXU material for regulatory testing. The company described these activities as part of a broader transition in 2026 from research-stage development into manufacturing, testing, and regulatory execution in preparation for a future submission.
The manufacturing program is intended to produce materials needed for a suite of regulatory and product characterization tests. Conexeu listed analytical work, chemical characterization, biocompatibility testing, sterilization studies, packaging evaluations, and other testing activities as those the manufacturing run will support in connection with the planned regulatory filing.
Regulatory timeline and interactions
Management said the company is continuing preparatory work for a planned 510(k) premarket notification submission to the U.S. Food and Drug Administration during the first quarter of 2027. Conexeu noted that it has received FDA pre-submission feedback through the agency’s Q-Submission process and that this advisory feedback has informed development planning for the company’s initial wound care indication. The company emphasized that FDA pre-submission feedback is advisory and does not represent a determination of substantial equivalence, marketing clearance, or approval.
The company also signaled that the timing of the 510(k) submission may be influenced by the results and timing of ongoing testing, execution of manufacturing activities, supplier readiness, and regulatory considerations.
Product platform
Conexeu’s lead candidate is built on the company’s proprietary CXU extracellular matrix platform. The CXU platform is described as a thermosensitive extracellular matrix that remains flowable during preparation and application, and then transitions into a gel scaffold at body temperature.
Executive commentary
Miles Harrison, the company’s chief executive officer and president, characterized the progress to date as reflecting maturation of the CXU platform and said it positions Conexeu to continue moving toward the planned first-quarter 2027 submission.
This article presents the company’s reported facts about manufacturing, regulatory planning, and product characteristics without additional commentary.